GC
TLIS

Greenlight Capital’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Greenlight Capital’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$1.11M Hold
149,052
– – 0.05% 36
2023
Q3 		$860K Hold
149,052
– – 0.05% 34
2023
Q2 		$1.07M Hold
149,052
– – 0.05% 35
2023
Q1 		$1.1M Hold
149,052
– – 0.06% 34
2022
Q4 		$996K Hold
149,052
– – 0.07% 32
2022
Q3 		$1.52M Hold
149,052
– – 0.11% 32
2022
Q2 		$1.82M Hold
149,052
– – 0.14% 37
2022
Q1 		$3.15M Buy
149,052
+44,432
+42% +$1.54M 0.2% 36
2021
Q4 		$6.29M Buy
+104,620
New +$7.83M 0.38% 32

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $155M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $77.3B AUM 36.07% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.3B AUM 62.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
Citigroup
Citigroup New York $157B AUM 32.99% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return